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Introduction: Prior studies have suggested that pacemaker reuse may be a reasonable alternative to
provide device therapy in the low- and middle-income countries. We studied explant indications and
remaining battery life of cardiac implantable electronic devices (CIEDs) at a tertiary medical center.
Methods and Results: We conducted a retrospective review of all CIEDs extracted at the University of
Michigan between 2007 and 2011. Devices were considered reusable if battery longevity was ≥48 months
or >75% battery life was remaining; there was no evidence of electrical malfunction, and they were not
under advisory or recall. Eight hundred and one CIEDs were explanted: Medtronic (MDT [Medtronic Inc.,
Minneapolis, MN, USA]; 454), Boston Scientific (BS [Boston Scientific Corp., Natick, MA, USA])/Guidant
(GDT; 255 [Guidant Corp., St. Paul, MN, USA]), St. Jude Medical (SJM; 73 [St. Paul, MN, USA]), and
Biotronik (BTK; 15 [Biotronik GmBH, Berlin, Germany]). After eliminating devices explanted for elective
replacement indicator (ERI, 541), 51.9% of pacemakers (41/79), 54.2% of implantable cardioverter-
defibrillators (ICDs) (64/118), and 47.6% of cardiac resynchronization therapy and defibrillation (CRT-D)
devices (30/63) had sufficient battery life and no evidence of electrical malfunction to be considered for
reuse. A logistic regression analysis found that the indications for device removal independently predicted
reusability: upgrade to an ICD (odds ratio [OR] 162.8, P < 0.001) or CRT-D (OR 63.8, P < 0.001), infection
(OR 110.7, P < 0.001), heart transplantation or left ventricular assist device placement (OR 56.6, P <
0.001), and device removal at patient’s request (OR 115.4, P < 0.001).
Conclusion: The majority of explanted CIEDs for reasons other than ERI have an adequate battery life
and, if proven safe, may conceivably be reutilized for basic pacing in underserved nations where access
to this life-saving therapy is limited. (PACE 2014; 37:569–575)
pacing, defibrillation – ICD
Pacemaker and implantable cardioverter-
defibrillator (ICD) use has been shown to reduce
morbidity and mortality in select patients with
cardiovascular disease.1,2 Cardiovascular disease
is not only the leading cause of death in the
high-income countries, but also in the devel-
oping world, where it causes twice as many
deaths as human immunodeficiency virus (HIV),
malaria, and tuberculosis combined.3 In some low-
and middle-income countries (LMIC), infectious
diseases such as Chagas or African Sleeping
Sickness add to the bradyarrhythmia burden.4,5
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Unfortunately, cost barriers prevent many patients
in the developing countries from benefiting from
cardiac implantable electronic devices (CIEDs).
The pacemaker and defibrillator implantation
rates are dramatically lower in LMIC. For instance,
in 2009, Peru and Bangladesh had implantation
rates of 30 and five pacemakers permillion people,
respectively, compared with 767 implants per
million population in the United States and 782
in France.6 The low implantation rates in LMIC
reflect poor access to electrophysiological care
due to a host of factors, one being the economic
conditions.
CIED reutilization has been proposed as a
means to eliminate the disparity in pacemaker
therapy between the industrialized world and
LMIC.7 This study explores the potential of
harvesting “good” devices at the time of CIED
removal for clinical indications. We examined the
reasons for explantation as well as the remaining
battery life of CIEDs explanted at a tertiarymedical
center. Any device with an adequate battery
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life and free from known malfunction could
potentially be reutilized in LMIC patients who
otherwise may not have access to this potentially
life-saving therapy.
Methods
A retrospective chart review was performed
on all CIEDs explanted at the University of
Michigan from January 2007 until January 2011.
Device parameters such as make, model, serial
number, battery voltage, percent pacing, pacing
thresholds, lead impedances, and time to charge,
when applicable, were collected. Parameters were
obtained at the time of, or within 3 months
prior to, CIED explantation. Patient demographics
and clinical data were also collected, including
age, sex, and indication for device implantation
and explantation. Criteria for a “reusable” device
were >75% of the original battery life or
≥48 months remaining and freedom from device
recall or failure. Battery longevity of Medtronic
Inc. (Minneapolis, MN, USA) ICDs and pacemak-
ers utilizing an ICD interrogation platform was
estimated by using the date of implant and battery
voltage as provided by Medtronic Technical
Services (personal communication, January 26,
2010). Battery longevity of some Guidant/Boston
Scientific devices (Guidant Corp., St. Paul, MN,
USA; Boston Scientific, Natick, MA, USA) are
expressed in descriptive terms: BOL (beginning
of life)/GOOD/OKAY/ERI (elective replacement
indicator) and as a “fuel gauge.” Voltages for these
devices were not included in the analysis. All of
the BOL devices were considered reusable. Any
device that was GOOD or OKAY was considered
reusable only if the fuel gauge showed 75% or
greater of the original battery life.
Statistical Analysis
Continuous variables were compared us-
ing the t-test, while categorical variables were
compared using the χ2 or Fisher exact test,
where appropriate. Logistic regression analysis
was performed to determine predictors of a
device being “reusable.” Analyses were performed
using SPSS (15.0) for Windows (IBM Corp.,
Armonk, NY, USA). P < 0.05 indicated statistical
significance.
Results
Device Data
During the study period, 2,452 device pro-
cedures were performed at the University of
Michigan. A total of 801 devices were explanted.
The manufacturers of the explanted generators
were Medtronic (MDT; 454), Boston Scien-
tific/Guidant (BS)/(GDT; 255), St. Jude Medical
(SJM; 73 [St. Paul,MN,USA]), andBiotronik (BTK;
15 [Biotronik GmBH, Berlin, Germany]). The name
of the manufacturer of four devices could not be
identified. Five hundred and forty-one devices
were explanted for ERI and 260 for all other
indications. Of the 801 devices, 13.2% (41/311) of
pacemakers, 21.0% (64/305) of ICDs, and 16.2%
(30/185) of cardiac resynchronization therapy
and defibrillation devices (CRT-Ds) had sufficient
battery life and no evidence of malfunction. After
eliminating the 541 devices explanted for ERI,
51.9% of pacemakers (41/79), 54.2% of ICDs
(64/118), and 47.6% of CRT-Ds (30/63) met the
criteria for reuse. Figure 1 shows the numbers of
reusable and nonreusable CIEDs according to the
device type and manufacturer among explanted
non-ERI devices in the study.
Figure 2 compares the average length of time,
in months, that nonreusable and reusable devices
remained inside their owner. Devices deemed
reusable were, on average, 4.5 years younger than
the nonreusable devices (average age of reusable
devices: 17.78 ± 1.77 months; average age of
nonreusable devices: 72.09 ± 2.26 months, P =
0.003).
A measure of the percent pacing found that
reusable devices had paced less than 50% of
the time (percent atrial pacing: 43.84% ± 6.55%;
percent ventricular pacing: 49.43% ± 5.20%).
The average pacing thresholds in the reusable
devices were fairly low (atrial pacing threshold:
1.01 ± 0.14 V at 0.45 ± 0.02 ms; right ventricular
pacing threshold: 1.15 ± 0.10 V, 0.48 ± 0.02
ms; left ventricular pacing threshold: 2.21 ±
0.43 V, 0.66 ± 0.10 ms). Average impedance
measurements were 520.9 ± 41.4 V in the atrium,
570.4 ± 34.2 V in the right ventricle, and 569.2 ±
53.0 V in the left ventricle. Table I lists the
indications for CIED explantation. Devices that
were explanted for infection, upgrade to a high
voltage and/or CRT device, lead failure, heart
transplant, or left ventricular assist device (LVAD)
implantationweremore likely to contain sufficient
battery life for potential reuse. A logistic regression
analysis determined that the following indications
for explantation were independent predictors for
a device being reusable: infection, an upgrade
to an ICD or CRT-D, heart transplant/LVAD
implantation, patient request, and lead failure
(Table II). SJM or BS/GDT devices were less
likely to meet the criteria for reuse, although the
finding for BS/GDT devices was not statistically
significant.
Patient Demographics
Younger patients were more likely to have
a reusable device (56.20 ± 1.49 and 61.21 ±
0.766 years for patients with a reusable and
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Figure 1. The number of reusable and nonreusable CIEDs according to the device type
and manufacturer among explanted non-ERI devices in the study. BS/GDT = Boston
Scientific/Guidant; BTK = Biotronik; CRT-D = cardiac resynchronization therapy—defibrillator;
CRT-P = cardiac resynchronization therapy—pacemaker; ERI = elective replacement indicator;
ICD = implantable cardioverter-defibrillator; MDT = Medtronic; SJM = St. Jude Medical.
Figure 2. The length of time, in months, from initial CIED implantation to generator removal for
non-ERI devices in the study. Abbreviations as in Figure 1.
nonreusable device, respectively, P = 0.007).
Males were 3.5 times mores likely to have a
reusable device than females (75.8% of males
vs 24.2% of females, P = 0.027). Tables III and
IV list the indications for ICDs and pacemakers,
respectively. Patients who had an ICD for primary
prevention of sudden cardiac death (nonischemic
cardiomyopathy [NICM] or ischemic cardiomy-
opathy [ICM]) were more likely to have a reusable
device than patients with initial ICD indication of
secondary prevention, although this did not reach
statistical significance (P = 0.058). There was no
difference in the indications for pacemakers in the
reusable versus the nonreusable devices.
Discussion
Cardiovascular disease is the leading cause of
death in the developing world.3 It is estimated
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Table I.
List of the Reasons for Explantation
Indication for Explantation Useable Devices (n = 135) Nonuseable Devices (n = 666) P-Value
ERI 0 (0.0%) 541 (81.2%) <0.001
Infection 43 (31.9%) 19 (2.4%) <0.001
Upgrade to ICD 13 (9.6%) 7 (1.0%) <0.001
Upgrade to CRT-D 27 (20.0%) 33 (5.0%) <0.001
Upgrade to dual-chamber pacemaker 1 (0.7%) 0 (0.0%) 0.024
Upgrade to CRT-pacemaker 3 (2.2%) 1 (0.1%) 0.002
Heart transplant/ LVAD implantation 25 (18.5%) 19 (2.9%) <0.001
Device failure 0 (0.0%) 16 (2.4%) 0.073
Lead failure 13 (9.6%) 26 (3.9%) 0.004
Device recall 0 (0.0%) 2 (0.3%) 0.529
Patient request 6 (4.4%) 6 (0.9%) 0.002
Devices explanted for reasons of an infection, an upgrade to a different device, a heart transplantation/LVAD implantation, a lead failure,
or because the patient no longer wants the device had a battery life ≥48 months. These devices were also free of malfunctions and thus
could potentially be reutilized. CRT-D = cardiac resynchronization therapy—defibrillator; ERI = elective replacement indicator; ICD =
implantable cardioverter-defibrillator; LVAD = left ventricular assist device.
Table II.
Results from a Logistic Regression Analysis, Which Was Used to Determine the Independent Predictors for Devices That
Could be Reutilized
Variable Odds Ratio (OR) P-Value
Device age (months) 0.929 <0.001
Patient age at explantation 0.998 0.832
Explanted for infection 110 <0.001
Explanted for upgrade to ICD 163 <0.001
Explanted for upgrade to CRT-D 63.8 <0.001
Explanted for heart transplant/ LVAD implantation 56.6 <0.001
Patient requested explantation 115 <0.001
Explanted for lead failure 40.6 <0.001
SJM device 0.216 0.012
GDT/BS device 0.251 0.252
Devices explanted for an infection, a device upgrade, heart transplant/LVAD implant, at the request of the patient, or lead failures
are overwhelmingly likely to meet the criteria for reuse. St. Jude Medical (SJM) devices were more likely to be reusable. GDT/BS =
Guidant/Boston Scientific. Other abbreviations as in Table I.
that about one million people die each year in
the world due to lack of access to pacemaker
therapy. The main finding of this study is that
nearly 50% of devices explanted in a tertiary
medical center for reasons other than ERI appear
free from malfunctions and have >75% of the
original battery life or at least 4 years of the battery
life remaining. These devices could potentially
be reutilized in patients in LMICs, where access
to bradyarrhythmia therapy is extremely limited.
The yield of reusable devices during non-ERI-
related device procedures (∼50%) is substantially
higher than among devices reclaimed postmortem,
where the yield of adequate battery life was only
21% for pacemakers and ICDs and 30% for CRT-
Ds.8 Should pacemaker or ICD reuse become
widely embraced, these findings would inform
refurbishing centers that devices obtained during
non-ERI-related device procedures should be a
major focus of their efforts. According to the
National Cardiovascular Data Registry (NCDR),
63,522 devices, representing about 41% of all ICD
generator procedures, were explanted annually
in years 2010–2012 (Personal Communication,
Paul Heidenreich, M.D., M.S. member, NCDR
Science & Quality Oversight Committee, NCDR R©
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Table III.
List of Patients’ Indications for Their ICD/CRT-D
Useable ICD/CRT-D Nonuseable ICD/CRT-D
Indication for ICD/CRT-D (n = 94) (n = 396) P-Value
Primary prevention of SCD 73 (77.6%) 268 (67.7%) 0.058
Secondary prevention of SCD 15 (16.0%) 91 (23.0%) 0.224
Other 6 (6.4%) 37 (9.3%) 0.806
Devices from patients with primary prevention indication were more likely to be suitable for reuse. SCD = sudden cardiac death. Other
abbreviations as in Table I.
Table IV.
List of Patients’ Indications for Their Pacemaker
Indication for Pacemaker Useable Pacemaker (n = 41) Nonuseable Pacemaker (n = 270) P-Value
Sick sinus syndrome 16 (39.0%) 99 (36.7%) 0.777
Atrioventricular block 23 (56.1%) 150 (55.6%) 0.999
Syncope 1 (2.4%) 7 (2.6%) 0.715
Carotid sinus hypersensitivity 0 (0.0%) 8 (3.0%) 0.318
Other 1 (2.4%) 6 (2.2%) 0.632
There was no significant correlation between patients’ indication and the reusability of their device.
ICD RegistryTM October 11, 2012). If the yield of
reusable ICD harvesting across the United States
is similar to that at the University of Michigan,
potentially asmany as 10,000–13,000 deviceswith
adequate battery life could be obtained each year
for donation.
In our series, the largest number of reusable
devices was due to infection followed by upgrade
to CRT-D and heart transplantation or LVAD
implantation. The rates of adequate battery life
are similar among pacemakers, ICDs, and CRT-
Ds (52%, 54%, and 48%, respectively). This
is unlike in the setting of postmortem device
collection, where CRT-D had substantially greater
remaining longevity than pacemakers and ICDs.8
The difference is likely explained by higher
disease acuity of patients in whom care is
escalated, as in upgrades to high voltage and resyn-
chronization therapy. The extraction indications
associated with the greatest chance of adequate
battery are upgrade to ICD, patient request for
device removal, and infection (odds ratio 163,
115, and 110, respectively). High battery voltages
commonly found in these devices would likely
translate into many years of use in patients with
bradyarrhythmia. This would especially be the
case for patients receiving an ICD or CRT-D device,
for the defibrillator function in these donated
devices would not be utilized.
Devices manufactured by SJM and BS/GDT
were less likely to meet the criteria for reuse in
this study, as indicated by the logistic regression
analysis, although this did not reach statistical
significance for BS/GDT. The reason for this is
not clear. It is possible that some patients with
Medtronic ICD generators underwent replace-
ments in advance of reaching ERI due to concern
about the Fidelis lead integrity.
Infected devices may be well suited for device
reutilization because the vast majority of those
devices are explanted within a few weeks of
implantation.9 Prior studies have shown that
infected devices, when properly handled and
sterilized, can be reutilized without significant
complications.10,11 Recently implanted devices
may have 10- to 12-year projected longevity,
highlighting the current waste of this costly
resource. Infected devicesmust undergo a rigorous
sterilization process. Further studies are needed to
prospectively examine safety of device reuse from
patients with device-related infections.
A recent study described an experience with
reprocessed devices obtained antemortem in 17
patients.12 Ten devices had been removed for
device upgrades and seven for infections. During
mean follow-up period of 68 ± 38 months,
no device infection or device malfunction was
observed. A meta-analysis compared the safety of
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new and reutilized devices in 2,270 patients across
18 trials.13 It found that, at 10 years, the overall
mortality of patients who received refurbished
devices was no higher than the mortality of
patientswith newdevices.Moreover, the infection
rate of the refurbished devices was no higher
than that with the new devices, around 1.97%.
The malfunction rate was higher in refurbished
devices, but it was still less than 1%. A rigorous,
large prospective trial of safety and efficacy of
device reuse is needed before device reuse can
gain wider acceptance as a means of charitable
support for patients in LMIC who cannot afford a
new pacemaker.
One other issue must be considered, as it
relates to device harvesting during non-ERI device
change-out and upgrade procedures. Who is the
owner the device? Is it the patient, the manufac-
turer, or the insurance scheme, which paid for
the device—whether it be private insurance or
Medicare/Medicaid? One can postulate that the
patient is the owner of the device. Even if a
third-party payment is considered, those funds
are raised through premiums and taxes, thus
indirectly paid by the patient.
The National Institutes of Health appear
to support the idea of patient ownership in
a consensus program regarding medical device
ownership.14 It seems intuitive that patient
consent is required prior to donation. Previous
research has found that about 90% of patients with
a CIED are willing to donate them if provided the
chance.8,15 The manufacturers encourage device
return for quality assurance and proper disposal.
Centers of excellence interested in device reuse
could return devices, which do not meet criteria
for reuse, to the manufacturers to assist in the
process of device analysis and proper disposal,
especially of the lithium battery component. Such
a collaborative approachwould allow for donation
of refurbished devices to needy patients in the
LMICs, as well as foster quality assurance and
proper device disposal.
It is important to note that CIED collection
and evaluation is only the first step in a long
and arduous journey to making device reuse a
reality. A validated cleaning and sterilization
protocol is needed to provide patients and
physicians with some degree of confidence that
the risk of infection would not be significantly
higher than with brand new pacemaker implants.
Additionally, given the unusual handling of
the devices, functionality testing must also be
developed and implemented to assure the integrity
of the CIED prior to reimplantation. A party with
experience in medical device reprocessing may
be needed to carry out key processes, and to
engage with regulatory bodies in the United States
(i.e., U.S. Food and Drug Administration) and
the recipient countries. Although implantation of
reprocessed devices goes on in many countries,
it often happens without the explicit sanctioning
by the health authorities. A nonprofit organization
may be created to raise funds necessary to
collect, reprocess, and distribute previously used
CIEDs. An additional role of the nonprofit would
be to assess qualification and safety record of
potential implanting centers and physicians, and
to maintain a database of all devices received and
distributed. In addition to cost of handling and
shipping, depending on the local infrastructure
and resources, partnerships with charitable orga-
nizations may help to cover the expense of the
leads and disposables if these are not available at
the implantation center. The implantation centers’
role would be to assess the indications for CIED
and patient’s financial status, safely implant the
devices, and provide follow-up monitoring and
detailed documentation on all devices. In short,
a great many legal and logistical obstacles will
have to be overcome through a collaborative
effort with multiple parties in order to offer
safe device implantation in patients with greatest
need.
Project My Heart Your Heart is commit-
ted to addressing these important issues by
furthering research in safe device reuse and
developing the necessary partnerships to allow
implementation of this concept. This organization
accepts devices from funeral homes, crematories,
hospitals, and family members of deceased device
patients. Potential donors can go to website
www.myheartyourheart.org to enter their contact
information and shipping address. This organi-
zation sends a prepaid self-addressed flat-rate
United States Postal Service envelope containing
biohazard bags for each device, instructions on
device removal, and how to return devices to
our center. We believe that the development of
standardized protocols for collection, evaluation,
and resterilization will make CIED reuse safe and
efficacious.
Limitations
Limitations of this study include the method
used to obtain our results. Direct battery measure-
ment with a load attached to the pacemaker was
not performed; rather, telemetry measurements
collected in the device clinic just prior to generator
change were analyzed. Direct battery measure-
ment would provide a more reliable battery
longevity assessment. Additionally, since device
parameters were collected within 3 months prior
to explanation, they may slightly overestimate the
true battery life potential.
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Conclusion
A large percentage of CIEDs explanted at
tertiary care centers have ample battery life
remaining. These devices could be reutilized to
patients in developing nations who cannot afford
a device. To ensure that devices can safely be
reused, a clinical trial should be performed, testing
the safety of the refurbished devices immediately
after implantation and at 6-month follow-up. If
successful, device reutilization has the potential to
save thousands of patients currently perishing due
to inaccessibility to a currently wasted resource.
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